Therapy with anti-CD20 monoclonal antibodies is highly efficacious in various autoimmune diseases including multiple sclerosis (MS), a prototypic autoimmune inflammatory disease of the central nervous system (CNS). However, which B cell subsets and altered B cell–regulating factors mediate the clinical efficacy of anti-CD20 treatment is unclear. To address this gap in knowledge, we performed longitudinal high-dimensional single-cell transcriptomic and proteomic profiling of blood, cerebrospinal fluid (CSF), and intestinal samples from people with MS (pwMS), combined with immune profiling in a preclinical autoimmune encephalomyelitis model during anti-CD20 therapy. CSF analyses were performed using previously published datasets. Multisite intestinal profiling was conducted in one anti-CD20–treated patient with MS and one control participant. By applying algorithm-guided analyses of flow cytometry, single-cell transcriptomic, and immune receptor repertoire data, we found that anti-CD20 B cell depletion was associated with increased frequencies of regulatory mucosal-derived IgA-producing B cells in the periphery and CSF, together with increased B cell receptor clonal overlap between mucosal and systemic compartments, indicating enhanced trafficking of IgA B cells from gut mucosal tissues to the systemic circulation and the CNS. Moreover, we demonstrated that higher levels of B cell–activating factor and a proliferation-inducing ligand were related to favorable outcomes in pwMS during anti-CD20 treatment. Together, our findings suggest that mucosal immune regulatory mechanisms may be harnessed by anti-CD20 B cell depletion, opening previously unknown therapeutic avenues for MS.
Fluid biomarkers detectable in cerebrospinal fluid (CSF) and blood offer critical insights into neurodegenerative disorders 1-5 , such as Alzheimer’s disease, frontotemporal dementia, and dementia with Lewy bodies 6-9 . Previous proximity-extension assay (PEA) studies have discovered 42 CSF biomarkers for distinguishing the aforementioned dementias 6-9 ; however, their disease- and matrix-specificity remain understudied. We developed and employed a federated meta-analysis framework to explore these biomarkers by analysing results from 65 case-control cohorts, including 20,576 samples (CSF n = 8,766, blood n = 11,810) covering 41 neurological and psychiatric conditions. Our comprehensive analysis identified both distinct and shared patterns of protein alterations across the spectrum of brain disorders, with marked differences observed between CSF and blood profiles. While several biomarkers demonstrated significant changes within their primary disease contexts, we also observed convergent dysregulation of proteins related to neuroinflammation and tau pathology across multiple conditions. These findings highlight the importance of fluid-specific biomarker assessment and provide a resource to inform the development and contextualization of novel biomarkers for brain disorders.